Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting
Date:10/29/2009

WAYNE, N.J. and EMERYVILLE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 25 studies evaluating the use of Nexavar® (sorafenib) tablets in liver cancer will be presented at The Liver Meeting®, the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Nexavar is the only systemic treatment to demonstrate prolonged survival in patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, and is currently approved in more than 80 countries for the treatment of the disease.

"Bayer and Onyx are committed to further evaluating Nexavar in patients with HCC to find the safest and most effective treatment regimens to help liver cancer patients better manage their disease," said Mark Gelder, vice president, Bayer Global Medical Affairs, Oncology. "While we are encouraged by the role Nexavar has played in treating these patients, we continue to evaluate Nexavar in a variety of treatment settings, including in combination with TACE and other systemic therapies, and as a monotherapy in the adjuvant setting."

Nexavar data highlights include:

Phase II Trial of Sorafenib Combined with Doxorubicin Eluting Bead-Transarterial Chemoembolization (DEB-TACE) for Patients with Hepatocellular Carcinoma (HCC): Interim Safety and Efficacy Analysis

  • Jean-Francois Henri Geschwind, The Johns Hopkins University School of Medicine, Baltimore, MD
  • Monday, November 2, 2009, 8:00 a.m. - 8:00 p.m., Exhibit Hall C
  • Late Breaker #9

First-in-men Demonstration of Sorafenib Plus TACE for the Treatment of Advanced Hepatocellular Carcinoma (SOCRATES trial)

  • Dr. Andreas Erhardt, Klinik fur
    '/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
2. Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
5. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
6. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
7. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
8. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
9. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... EVANSTON, Ill. , Sept. 2, 2015 ... and a frenzy of health care M&A activity – ... place moderate-to-severe access restrictions on pharmaceutical sales reps. This ... who limit access has crossed the halfway point, according ... global sales and marketing firm ZS . ...
(Date:9/2/2015)... MENLO PARK, Calif. , Sept. 2, ... DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... cancer therapies, today announced that it will present ... Mechanisms and Cytotoxic Activity of Dianhydrogalactitol (VAL-083) to ... Mutant p53," at the American Association for ...
(Date:9/2/2015)... 2, 2015 CytoSorbents Corporation (NASDAQ: CTSO ... ® blood purification technology to reduce deadly uncontrolled ... CEO Dr. Phillip Chan , MD, PhD, will ... Conference (sponsored by H.C. Wainwright & Co) ... York City.  Currently, the management team ...
Breaking Medicine Technology:Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 2DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 3DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 4CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 2CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 3CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 4
... for Clinical Research, Inc., a company leading the industry ... announced today that CEO Dr. Marcus Hompesch is an ... and ISCR,s 4th Annual Clinical Research Conference in February. ... be held February 1-4 in Ahmedabad, India and is ...
... Md., Jan. 26, 2011 RNL BIO CO., LTD, a ... on January 21, 2011 another successful patient report utilizing stem ... suffered from Autoimmune Arthritis.   Dr. Stanley ... sudden onset of acute pain in his wrist in September ...
Cached Medicine Technology:Profil Institute's CEO Presenting on Early Phase Clinical Research in India 2Profil Institute's CEO Presenting on Early Phase Clinical Research in India 3American Orthopedic Spine Surgeon Successfully Treated for Autoimmune Arthritis with His Own Stem Cells 2
(Date:9/2/2015)... ... September 02, 2015 , ... Alameda County Community Food Bank ... Month” during the entire month of September. In the spirit of the ... efforts this September to an awareness campaign educating legislators and the public on ...
(Date:9/2/2015)... Norcross, GA (PRWEB) , ... September 02, 2015 ... ... Aflac Cancer Center at Children's Healthcare of Atlanta to help support ... C.H.O.A. to discuss the upcoming WSB Radio Care-A-Thon , which is the ...
(Date:9/2/2015)... Neb. (PRWEB) , ... September ... ... of the nation’s largest and fastest-growing interim clinical staffing companies, has completed ... and Heritage Group.         , BPOC and Heritage Group each offer ...
(Date:9/2/2015)... ... September 02, 2015 , ... Every year at this time, students prepare to ... are prepared to face the academic workload confronting them. They just don’t have the ... since schools don’t teach students how to study. , “Bankers bank. Salesmen sell. Teachers ...
(Date:9/2/2015)... Destin, Florida (PRWEB) , ... September 02, 2015 , ... ... in drug prices over the past year and its negative impact on consumers. It ... regular prescription medication and 10% were paying as much as an extra $100 compared ...
Breaking Medicine News(10 mins):Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2
... sooner in unions where anger is suppressed , , FRIDAY, Feb. ... long marriage is communication, and new research now notes it,s ... study of Midwestern couples finds that those who felt free ... The couples with the most unexpressed anger died the earliest. ...
... will be the only one if its kind in ... Seattle Cancer Care Alliance (SCCA),and Northwest Hospital & Medical ... to explore the development of a new, state-of-the-art,cancer treatment ... announced its intention to develop a proton-therapy,facility in September ...
... WARSAW, Ind., Feb. 8 Symmetry Medical Inc.,(NYSE: ... the global,orthopedic device industry and other medical markets, today ... update press release on,February 14, 2008 before the opening ... accompanying conference call at 8:00 a.m. ET on,February 14, ...
... study of pregnant women, those with pregnancy-induced high blood ... peptide that raises blood pressure in the pieces of ... Wake Forest University Baptist Medical Center. The finding, reported ... the disorder develops. , Preeclampsia, or high blood pressure ...
... TSX: BMR, TORONTO, Feb. 8 /PRNewswire-FirstCall/ - ... development and,commercialization of cancer therapies, today announced that ... of the Company, will,participate as a presenter and ... Conference. Dr. Ezrin will provide an update on ...
... Mich., Feb. 8 Amigo Mobility, a,leading manufacturer ... ), a manufacturer of polyurethane tires and tire ... will be,featured as original equipment on the Amigo ... supply Amigo Mobility with,approximately 25,000 tires per year., ...
Cached Medicine News:Health News:Mutual Resentment in Marriage Can Be Deadly 2Health News:Mutual Resentment in Marriage Can Be Deadly 3Health News:Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment 2Health News:Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment 3Health News:Symmetry Medical to Provide Fourth Quarter 2007 General Business Update on February 14, 2008 2Health News:New finding may help explain development of preeclampsia 2Health News:Bradmer to present at the 10th Annual BIO CEO & Investor Conference 2Health News:Amigo Mobility Selects Amerityre as OEM Supplier 2Health News:Amigo Mobility Selects Amerityre as OEM Supplier 3
...
...
... At the entry-level, Philips Zymed 1810 Series ... preview, which gives the operator the flexibility ... complex arrhythmia. Choose an application beyond the ... flexibility. Select the interactive or automatic style ...
... Zymed 2010 plus Holter Software for ... application as easy to install, use ... data presentation as comprehensive as a ... superimposition, prospective paging and QuickScan, which ...
Medicine Products: